The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for co-dydramol. Previously co-dydramol (dihydrocodeine/paracetamol) was available only in the ratio 1:50 (co-dydramol 10/500 mg). Two products are now available with a higher strength of dihydrocodeine (co-dydramol 20/500 mg and 30/500 mg tablets). It is therefore important that co-dydramol products are prescribed and dispensed by strength to minimise dispensing errors and the risk of accidental opioid overdose.
Some of our content, including support alerts, is only available to RPS members.
Find out more about membership of the Society